pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ROCHE · news · pharmadog
← back to ROCHE
News mentioning ROCHE
260
stories
13d
STAT+: A private equity-owned hospital chain is becoming a nonprofit. Is it just a bailout for investors?
stat
13d
Pharmas face off for manufacturing talent amidst reshoring efforts
biospace
13d
Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market
fiercebiotech
13d
STAT+: HHS unveils new initiatives to reduce animal testing in drug development
stat
14d
STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program
stat
14d
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
biospace
14d
STAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and more
stat
14d
Roche reports Phase 2 enicepatide data in overweight or obese patients with diabetes
endpoints
14d
STAT+: Ohio governor’s race is a battle over Covid, health costs, and trust in science
stat
14d
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
fiercebiotech
14d
STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators
stat
15d
STAT+: Lilly’s breast cancer combo wins approval
stat
15d
STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial
stat
15d
Citing Replimune approval, experts say localized cancer meds could redefine care
biospace
15d
Cue chalks up phase 2 hives win for Xolair challenger
fiercebiotech
15d
STAT+: Radiopharma companies merge after one receives surprise FDA rejection
stat
17d
Jehovah’s Witnesses allow blood-derived products but keep ban on whole-blood transfusions
stat
18d
This week in charts: GSK’s China deals, the $300M IPO club and selling the news
biopharma dive
18d
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
biopharma dive
18d
STAT+: Roche expands its Boston footprint with new research center
stat
18d
BMS scraps Orum’s targeted degrader after reviewing Phase 1 data
biospace
19d
Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win
endpoints
19d
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
biospace
19d
Roche bets up to $1B to advance next-gen bispecifics with Dualitas
biospace
19d
Roche turns to Dualitas to find new bispecific approaches for immunology
endpoints
19d
Roche, Dualitas team up to find bispecific drugs for immune diseases
biopharma dive
19d
Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
fiercebiotech
20d
Novo looks to Anthropic’s AI models to ‘supercharge’ drug development
biopharma dive
20d
Skyhawk racks up more support for Huntington’s drug
biopharma dive
20d
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
biospace
← prev
page 3 of 9
next →
